Adding the PAN-AKT inhibitor MK-2206 to standard neoadjuvant therapy also improved the estimated pCR rates in HR-negative and HER2-positive early breast cancer patients (Chien et al., 2020). This evidence concerns the gene ERBB2 and breast cancer.